Form 4: Puma Biotechnology Director Sells 27,000 Shares Under 10b5-1 Plan

Adrian Senderowicz, a director at Puma Biotechnology, sold 27,000 shares of common stock at a weighted average price of $3.3266 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 13, 2024, Adrian Senderowicz, a director of Puma Biotechnology, sold 27,000 shares of the company's common stock.
• The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 15, 2023.
• The shares were sold at a weighted average price of $3.3266, with individual transaction prices ranging from $3.2801 to $3.5401.
• Following the transaction, Senderowicz directly owns 0 shares of Puma Biotechnology.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 plan suggests the director planned the sales in advance to avoid accusations of insider trading. It is common for directors to diversify their holdings or exercise stock options.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates